Long Term Combination Treatment With Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature

Long Term Combination Treatment With Bevacizumab, Pegylated Liposomal Doxorubicin and Regional Abdominal Hyperthermia in Platinum Refractory Ovarian Cancer: A Case Report and Review of the Literature

Platinum resistance constitutes a therapeutic challenge in the treatment of ovarian cancer, with overall unsatisfactory response rates to standard chemotherapy and correspondingly low survival. Regional abdominal hyperthermia and bevacizumab are treatment options that have both shown the capacity to...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research Vol. 31; no. 8; pp. 2675 - 2677
Main Authors: PIETZNER, Klaus, BIANCA SCHMUCK, Rosa, FOTOPOULOU, Christina, GELLERMANN, Johanna, ISMAEEL, Fakher, HEE CHO, Chie, KALDEN, Michael, SEHOULI, Jalid
Format: Conference Proceeding Journal Article
Language:English
Published: Attiki International Institute of Anticancer Research 01-08-2011
Subjects:
Abdomen
Adult
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Biological and medical sciences
Doxorubicin - administration & dosage
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Hyperthermia, Induced
Medical sciences
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - therapy
Tumors
Antineoplastic agent
Ovary cancer
Monoclonal antibody
Regional
Doxorubicin
Bevacizumab
Isomerases
Cancerology
Platinum
platinum-refractory
Antiangiogenic agent
Pegylated form
DNA topoisomerase (ATP-hydrolysing)
Treatment resistance
Enzyme
ovarian cancer
Enzyme inhibitor
Liposome
Topoisomerase II inhibitor
Malignant tumor
Long term
Female genital diseases
Abdomen
Case study
Ovarian diseases
Vascular endothelium growth factor
Treatment
Anthracyclins
Hyperthermia
Bibliographic review
Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Platinum resistance constitutes a therapeutic challenge in the treatment of ovarian cancer, with overall unsatisfactory response rates to standard chemotherapy and correspondingly low survival. Regional abdominal hyperthermia and bevacizumab are treatment options that have both shown the capacity to improve the results of standard chemotherapy in the platinum-resistant situation, when added to the treatment schedule. We report on a 29-year-old patient with primary platinum-refractory ovarian cancer, who was treated with a combination of pegylated liposomal doxorubicin, regional abdominal hyperthermia and bevacizumab in a four-week cycle over a long-term period of 38 months. Due to an excellent clinical and radiologic response resulting in stable disease, with a concomitant mild toxicity profile consisting only of intermitted diarrhoea and mild fatigue [corrected] , the treatment was continued in an ambulatory setting. To our knowledge we describe the first experience with combination treatment of pegylated liposomal doxorubicin with regional abdominal hyperthermia and bevacizumab in a long term setting of almost 2 years. Excellent response with comparably low toxicity was demonstrated. Further evaluation as a therapeutic option in this heavily pretreated and highly palliative patient population is warranted.
ISSN:0250-7005
1791-7530